Roche vs NATCO: India’s First "Doha Style" Compulsory License?
Most of you may have heard of the first “Doha” style compulsory license for export of GSK’s ARV drug, TriAvir from Canada to Rwanda. For a great summary of this case, see this ASIL article. Latha Jishnu of the Business Standard reports that a similar request is being made by Natco Pharma, an Indian generic company, to export Roche’s anti cancer drug, Tarceva (Erlotinib) from India to Nepal. The application is for the export of 30,000 tablets to Nepal and […]
Roche vs NATCO: India’s First "Doha Style" Compulsory License? Read More »




